Filing Flows › Verrica Pharmaceuticals (VRCA) › Q1 2026
Verrica Pharmaceuticals (VRCA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Verrica Pharmaceuticals (VRCA) reported revenue of $5.0M for the first quarter 2026 (Q1 2026), +46% from a year earlier and -1% from the quarter before. Operating margin was -193.4%, net loss $9.7M (192.8% of revenue).
Verrica Pharmaceuticals, Q1 2026: revenue $5.0M (+46% year over year), operating margin -193.4%, net loss $9.7M, operating cash flow −$9.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | -1% | +46% |
| Operating profit | −$9.7M | — | — |
| Net earnings | −$9.7M | — | — |
| Operating cash flow | −$9.2M | — | — |
What changed
Revenue was $5.0M in Q1 2026, up 46% year over year and down 1% from the previous quarter. Product revenue, net was the largest line at 85% of revenue. Product revenue, net added $868K year over year (up 25%), 55% of the total change.
Operating costs exceeded revenue by $9.7M, an operating margin of -193.4%. Total costs grew 27% against revenue growth of 46%. The quarter ended with a net loss of $9.7M, wider than the previous quarter's $8.1M loss.
Operating cash flow was −$9.2M. Non-cash charges added back $17K of depreciation and $897K of share-based compensation.
Questions
What was Verrica Pharmaceuticals' revenue in the first quarter 2026?
Verrica Pharmaceuticals (VRCA) reported revenue of $5.0M for the first quarter 2026 (Q1 2026), +46% from a year earlier and -1% from the quarter before.
Was Verrica Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $9.7M (-193.4% of revenue) and net loss $9.7M.